List of Excipients in Branded Drug SOTALOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ALTATHERA Pharmaceuticals LLC	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	69724-112	ACETIC ACID
ALTATHERA Pharmaceuticals LLC	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	69724-112	SODIUM HYDROXIDE
ALTATHERA Pharmaceuticals LLC	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	69724-112	WATER

Generic Drugs Containing SOTALOL

Company	Ingredient	NDC	Excipient
Marlex Pharmaceuticals Inc	sotalol hydrochloride	10135-661	CELLULOSE, MICROCRYSTALLINE
Marlex Pharmaceuticals Inc	sotalol hydrochloride	10135-661	FD&C BLUE NO. 2
Marlex Pharmaceuticals Inc	sotalol hydrochloride	10135-661	LACTOSE MONOHYDRATE
Marlex Pharmaceuticals Inc	sotalol hydrochloride	10135-661	MAGNESIUM STEARATE
Marlex Pharmaceuticals Inc	sotalol hydrochloride	10135-661	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in SOTALOL?

# Of NDCs	Excipient
7	CELLULOSE, MICROCRYSTALLINE
7	FD&C BLUE NO. 2
7	LACTOSE MONOHYDRATE
7	MAGNESIUM STEARATE
7	SILICON DIOXIDE

Sotalol Excipient Strategy and Commercial Opportunities

Last updated: September 20, 2026

Sotalol is a mature, genericized antiarrhythmic with limited active-substance patent protection and a larger opportunity in formulation differentiation. The strongest commercial positions are likely to come from dose-flexible liquids, low-volume pediatric or geriatric presentations, ready-to-use injectable products, adherence-oriented packaging, and excipient systems that improve stability without altering sotalol exposure.

Sotalol hydrochloride is marketed primarily as immediate-release tablets, oral solution, and intravenous injection. The drug has two commercial uses: treatment of ventricular arrhythmias and maintenance of normal sinus rhythm in patients with atrial fibrillation or atrial flutter. Its principal formulation constraint is cardiac safety. Sotalol prolongs the QT interval, and renal impairment materially increases exposure. Excipient choices therefore need to preserve dose accuracy, dissolution, stability, and predictable pharmacokinetics rather than pursue aggressive absorption enhancement.

What is the regulatory status of sotalol?

Sotalol hydrochloride is an FDA-approved prescription antiarrhythmic available through abbreviated new drug applications, 505(b)(2) products, and product-specific formulations.

Product type	Typical strength or presentation	Regulatory role	Commercial status
Immediate-release tablets	80 mg, 120 mg, 160 mg, 240 mg	Generic ANDA products and branded historical products	Mature generic market
Oral solution	5 mg/mL	FDA-approved liquid formulation, including Sotylize	Differentiated dosage form
Intravenous injection	Commonly 150 mg/10 mL, depending on product	Hospital initiation or reinitiation	Specialty hospital product
Compounded liquid	Variable concentration	Pharmacy-compounded alternative	Quality and stability vary by pharmacy

FDA labeling requires inpatient initiation or reinitiation for many sotalol regimens because of QT prolongation and the risk of serious ventricular arrhythmias. The label also requires renal-function-based dosing and electrocardiographic monitoring during initiation. These requirements create a commercial opportunity for formulations that reduce preparation error but do not eliminate the need for monitoring. (U.S. Food and Drug Administration, 2023a, 2023b)

How does sotalol differ from other antiarrhythmic drugs?

Sotalol combines nonselective beta-adrenergic blockade with Class III potassium-channel blocking activity. Unlike many chronic cardiovascular drugs, its safety profile makes excipient and formulation consistency commercially relevant.

Drug	Main formulation issue	Excipient opportunity
Sotalol	QT prolongation, renal clearance, narrow safety margin during initiation	Dose accuracy, liquid stability, hospital-ready injection
Amiodarone	High tissue accumulation, complex loading, poorly soluble active ingredient	Solubilization and tissue-exposure control
Dofetilide	QT prolongation and renal dosing	Capsule consistency and adherence support
Flecainide	Dose-dependent proarrhythmic risk	Immediate-release dose flexibility
Propafenone	Extensive metabolism and food effects	Modified release and tolerability

Sotalol does not require a complex solubilization platform. The commercial value is more likely to arise from manufacturing reliability, flexible dosing, and reduced medication-use error.

What excipients are used in sotalol formulations?

Sotalol tablets generally use conventional solid-dose excipients. The exact composition varies by manufacturer and strength. Common functional categories include fillers, binders, disintegrants, glidants, and lubricants. Lactose, microcrystalline cellulose, starch derivatives, povidone, colloidal silicon dioxide, and magnesium stearate are examples found across generic immediate-release tablet systems, but a manufacturer’s approved formulation must be confirmed in its product labeling and regulatory filing.

Sotalol oral solutions use aqueous vehicles and may contain sweeteners, buffering agents, flavoring systems, and viscosity or tonicity modifiers. The FDA-approved Sotylize label identifies a 5 mg/mL oral solution and its inactive-ingredient system. Sorbitol and high-intensity sweetening systems are commercially relevant because palatability and dose measurement determine whether a liquid can compete with tablets. (U.S. Food and Drug Administration, 2014)

Injectable products require the tightest excipient controls. Relevant attributes include pH, osmolality, particulate burden, container compatibility, extractables and leachables, and sterilization stability. A hospital injectable should minimize bedside preparation and avoid excipients associated with hypersensitivity or clinically significant metabolic effects.

Which excipient attributes matter most for sotalol?

Attribute	Why it matters for sotalol	Commercial implication
Dose uniformity	Small dosing errors can affect QT exposure	Strong value for liquids and low-dose tablets
Dissolution consistency	Exposure must remain predictable across strengths	Supports robust immediate-release systems
Chemical stability	Degradation may compromise potency or impurity profile	Important for aqueous liquids and injectables
Palatability	Poor taste reduces adherence, particularly in children and older adults	Supports flavored, sweetened liquid systems
Osmolality	High osmolality can limit injection tolerability	Relevant to ready-to-use IV products
Excipient safety	Renal, diabetic, pediatric, and geriatric populations may be sensitive to certain excipients	Favors low-sugar and low-electrolyte designs
Packaging compatibility	Sorption, leaching, and moisture ingress can change product quality	Supports premium container-closure systems

What formulations are protected by sotalol patents?

Sotalol’s core active-substance protection is long expired. The molecule has been used clinically for decades, and standard immediate-release tablets are exposed to extensive generic competition. New commercial protection would need to attach to a specific formulation, delivery system, manufacturing process, device, or clinically differentiated use.

The most defensible patent targets are:

1. A chemically stable oral solution with a defined pH range and preservative-free shelf life.
2. A taste-masked liquid using a specific sweetener, flavor, complexing agent, or multilayer system.
3. A low-volume pediatric formulation with a calibrated oral syringe and concentration designed around weight- or body-surface-area-based dosing.
4. A ready-to-administer intravenous presentation with defined osmolality and container-closure performance.
5. A moisture-resistant tablet or unit-dose package that improves stability in high-humidity markets.
6. A manufacturing process that reduces a specific impurity or controls polymorphic form.
7. A formulation that maintains dissolution after extended storage or under stress conditions.

A formulation patent must provide a measurable technical advantage. Broad claims covering sotalol with routine excipients are vulnerable to obviousness challenges, especially when the same excipients are conventional in immediate-release tablets or oral solutions.

How many patents cover sotalol?

The commercially important patent count is low compared with newer cardiovascular drugs. The original active-ingredient protection and any associated regulatory exclusivity have expired. Current freedom-to-operate analysis should focus on product-specific patents listed in the FDA Orange Book, formulation patents, manufacturing patents, and device or packaging claims rather than the sotalol molecule itself. (U.S. Food and Drug Administration, 2024)

For a new entrant, the relevant IP question is not whether sotalol is patented in the abstract. It is whether a proposed concentration, excipient combination, process, container, or dosing presentation falls within an unexpired claim.

When does sotalol lose exclusivity?

Sotalol has already lost basic market exclusivity. Generic tablet competition has existed for many years, and no new chemical entity exclusivity remains.

Exclusivity category	Status
Active-ingredient patent	Expired
NCE exclusivity	Expired
Conventional tablet generic entry	Established
Oral-solution exclusivity	Expired or no longer commercially material
IV formulation exclusivity	Any limited regulatory exclusivity associated with later approval is no longer a durable market barrier
Formulation patents	Product-specific; must be assessed claim by claim
Orphan-drug exclusivity	Not a principal protection mechanism for standard sotalol products

The FDA approved Sotylize, a 5 mg/mL oral solution, in 2014. Any three-year exclusivity tied to new clinical investigations supporting that approval would have expired. The FDA approved an intravenous sotalol product in 2020, but any related regulatory exclusivity would not provide a current long-term barrier to a technically distinct competitor. (U.S. Food and Drug Administration, 2014; U.S. Food and Drug Administration, 2020)

What is the Orange Book status of sotalol?

The Orange Book is relevant for identifying approved drug products, therapeutic-equivalence ratings, and any listed patents or exclusivity. Standard sotalol tablets are generally positioned as conventional multisource products. The main Orange Book risk for a new formulation is not the old tablet market. It is a listed patent attached to a specific oral solution, injectable product, or other differentiated presentation.

A potential generic applicant should evaluate:

• Listed patents for the reference oral solution or injection.
• Paragraph IV certification exposure.
• Whether the proposed product is therapeutically equivalent to the reference product.
• Whether a new concentration requires a separate application or a 505(b)(2) pathway.
• Labeling differences involving pediatric use, measuring devices, preservatives, or administration instructions.
• Drug master file and excipient documentation for novel excipient systems.

What paragraph IV challenges and litigation affect sotalol?

Sotalol’s conventional tablet market is unlikely to generate major new patent litigation because the core product is old and heavily genericized. Litigation risk is more likely for a differentiated liquid or injectable product if an innovator lists formulation patents in the Orange Book.

A Paragraph IV strategy would be most relevant where:

• The reference product has an unexpired formulation patent.
• The proposed formulation uses a different excipient system but remains pharmaceutically equivalent.
• The applicant can challenge claim scope, written description, enablement, or obviousness.
• The commercial prize justifies litigation costs.

For a low-price generic tablet, litigation economics are weak. For a hospital injectable, pediatric liquid, or protected device combination, the potential market may justify an early patent challenge. No major, widely reported current patent dispute is a central barrier to ordinary sotalol tablet entry based on the drug’s mature market position.

What generic entry risks exist for sotalol?

Generic entry risk is high for standard tablets and lower for differentiated presentations.

Immediate-release tablets

Tablet competition is intense. Buyers can switch among multiple approved manufacturers, and price is the main procurement variable. New entrants need manufacturing scale, reliable supply, and competitive cost rather than a novel excipient platform.

Oral solution

The liquid market is more defensible because manufacturing, taste, stability, microbial control, and device compatibility raise development costs. The principal risks are:

• Substitution with pharmacy-compounded liquid.
• Low prescription volume.
• Reimbursement pressure.
• Product-specific patent claims.
• Stability failures during in-use testing.
• Excipient restrictions in children, older adults, or patients with diabetes.

Intravenous injection

The IV market has higher technical and operational barriers. Suppliers must meet sterile manufacturing, container-closure, particulate, and supply-continuity requirements. Hospitals may favor ready-to-use or easy-to-dilute presentations, but the addressable volume is lower than for tablets.

What commercial opportunities exist for sotalol excipients?

Pediatric and geriatric oral liquids

A 5 mg/mL product is useful for patients unable to swallow tablets and for dose adjustments. A differentiated product could offer:

• A calibrated oral syringe.
• Low-volume dosing.
• Improved taste masking.
• Sugar-free formulation.
• Reduced sorbitol load.
• Preservative-free multidose packaging where stability permits.
• Child-resistant packaging with accessible labeling.
• Dosing instructions tied to renal function and body size.

The strongest opportunity is not a higher concentration alone. It is a complete medication-use system that reduces measurement and administration errors.

Ready-to-use hospital injection

A ready-to-use IV product could compete on workflow. Potential advantages include:

• No bedside reconstitution.
• Standardized concentration.
• Lower preparation burden.
• Reduced pharmacy compounding.
• Clear renal-dose adjustment instructions.
• Barcoded unit-dose packaging.
• Compatibility data for common infusion systems.

A ready-to-use formulation must avoid creating a false perception that monitoring is unnecessary. Sotalol initiation still requires electrocardiographic and renal assessment.

Improved tablet performance

The tablet market offers fewer opportunities, but excipient engineering can improve:

• Mechanical strength at lower tablet weight.
• Fast disintegration.
• Moisture protection.
• Dose uniformity across multiple strengths.
• Reduced tablet size.
• Lower friability during automated packaging.
• Compatibility with unit-dose hospital packaging.

An orally disintegrating tablet is a possible niche, but it would need to demonstrate meaningful advantages over standard tablets and oral solution. Taste, tablet robustness, and dose accuracy would determine commercial value.

Global-market formulations

Low-resource and high-humidity markets may favor:

• Aluminum-aluminum blister packs.
• Desiccant-integrated bottles.
• Stable oral liquids that do not require refrigeration.
• High-temperature stress stability.
• Simple dosing devices.
• Excipient systems compatible with local regulatory requirements.

A formulation with a 24- or 36-month shelf life under demanding climatic conditions could create a procurement advantage even without broad patent protection.

How strong is the patent estate for sotalol?

The patent estate is weak for the active ingredient and conventional tablets. It can be moderate for a carefully developed formulation with technical data and narrow claims.

IP asset	Relative strength	Main risk
Sotalol active ingredient	Very low	Expired protection
Conventional tablet	Low	Obviousness and generic substitution
Standard oral solution	Low to moderate	Routine excipient combinations
Novel taste-masked liquid	Moderate	Claim breadth and clinical relevance
Ready-to-use injectable	Moderate	Prior art and hospital economics
Specialized packaging	Moderate	Design-around risk
Manufacturing impurity-control process	Moderate to high if technically specific	Enablement and proof of benefit
Device-linked dosing system	Moderate	Device and drug claims may be separable

The best strategy is a layered portfolio. One patent should cover the composition, another the concentration and pH window, and a third the container or dosing device where justified. Trade-secret protection can supplement patents for mixing order, process controls, and impurity management.

Which companies are challenging or competing with sotalol?

Competition is fragmented across generic tablet manufacturers, specialty pharmaceutical companies, hospital suppliers, and compounders. The relevant competitor set includes:

• Generic manufacturers selling sotalol hydrochloride tablets.
• Suppliers of FDA-approved sotalol oral solution.
• Hospital injectable manufacturers.
• Compounding pharmacies offering customized concentrations.
• Alternative antiarrhythmic products such as amiodarone, dofetilide, flecainide, and propafenone.

Because sotalol is usually sold as a generic, public-company revenue disclosures rarely isolate the product. Revenue exposure is therefore best assessed through prescription volume, National Average Drug Acquisition Cost data, wholesaler pricing, hospital contract awards, and shortage history rather than issuer-level financial statements. (U.S. Food and Drug Administration, 2023c)

What licensing deals could support a sotalol formulation?

A licensing transaction would be most credible for a differentiated dosage form, not for ordinary tablets. Potential deal structures include:

• An excipient supplier licensing a taste-masking or stability platform.
• A specialty pharmaceutical company licensing an oral solution with commercial rights by territory.
• A hospital-product company licensing a ready-to-use injectable.
• A device company partnering on an oral syringe, cup, or smart dispensing system.
• A contract manufacturer supplying sterile sotalol injection under a technology-transfer agreement.

Commercial diligence should prioritize exclusivity of the formulation claims, stability data, regulatory pathway, manufacturing yield, minimum order quantities, and reimbursement. A platform license without product-specific sotalol data has limited value.

What is the best commercial strategy for a new sotalol product?

The strongest strategy is a differentiated, low-complexity product with measurable workflow or adherence benefits.

1. Avoid competing solely on standard tablets unless the manufacturer has a clear cost or supply advantage.
2. Prioritize a stable, palatable oral solution with a calibrated dosing device.
3. Consider a ready-to-use injectable for hospital initiation and reinitiation.
4. Build excipient selection around renal, pediatric, diabetic, and geriatric populations.
5. Generate comparative stability, dose-uniformity, in-use, and administration-error data.
6. File narrow formulation and process patents supported by analytical evidence.
7. Use packaging and device claims to supplement composition claims.
8. Target markets where liquid availability, hospital preparation, or supply reliability is a recognized problem.

Key Takeaways

• Sotalol’s active ingredient and conventional tablet market are mature and largely unprotected.
• Excipient strategy is more valuable in oral liquids and injectables than in standard tablets.
• The principal technical priorities are dose accuracy, stability, palatability, osmolality, and container compatibility.
• A 5 mg/mL oral solution with a strong dosing device and improved tolerability is the clearest outpatient opportunity.
• A ready-to-use IV presentation is the clearest hospital opportunity.
• Patent value will depend on specific formulation, process, packaging, or device claims.
• Standard tablet entry faces high generic competition and limited pricing power.
• Regulatory and commercial differentiation must be supported by measurable reduction in preparation error, dosing burden, or stability risk.

FAQs

Can sotalol be reformulated with a different excipient system?

Yes. A different excipient system may support an ANDA, 505(b)(2) application, or another regulatory pathway depending on dosage form, concentration, labeling, and equivalence. The formulation must preserve product quality and clinically acceptable exposure.

Is a preservative-free sotalol oral solution commercially attractive?

It can be attractive for pediatric, geriatric, and preservative-sensitive populations, but the product must demonstrate microbiological integrity throughout its shelf life and in-use period. Single-dose packaging may improve the feasibility of a preservative-free design.

Could a high-concentration sotalol liquid reduce formulation costs?

Potentially, because it may reduce bottle size, shipping volume, and dose volume. The tradeoff is increased dosing risk, taste intensity, solubility constraints, and the need for a more precise measuring device.

Does sotalol require a novel excipient to obtain market differentiation?

No. Differentiation can come from a defined combination of approved excipients, a superior container, a dosing device, a ready-to-use injectable format, or validated stability and administration performance.

Is sotalol a good candidate for an extended-release formulation?

It is technically possible, but the commercial case is uncertain. Extended release would need to demonstrate a meaningful clinical or adherence advantage while maintaining predictable exposure in patients with varying renal function. Immediate-release products and existing dose-adjustment requirements create a high development burden.

References

1. U.S. Food and Drug Administration. (2014). Sotylize (sotalol hydrochloride) oral solution prescribing information. FDA.

2. U.S. Food and Drug Administration. (2020). Sotalol hydrochloride injection prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023a). Betapace and Betapace AF (sotalol hydrochloride) prescribing information. FDA.

4. U.S. Food and Drug Administration. (2023b). Sotalol hydrochloride tablets prescribing information. FDA.

5. U.S. Food and Drug Administration. (2023c). Drug shortages: Sotalol hydrochloride injection and related product information. FDA.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.